Ranbaxy partners with Cipher to market acne drug

As per the agreement, Ranbaxy will be responsible for all the marketing, sales and distribution activities of Cipher's acne drug in Brazil

pact

Ranbaxy plans to promote the product through a brand dermatology division in Brazil

Ranbaxy Laboratories announced that it had signed a licensing agreement with Cipher Pharmaceuticals to exclusively market, sell and distribute Cipher's isotretinoin capsules in Brazil.

Commenting on the partnership, Mr Sanjeev I Dani, executive VP and head, global strategy, Ranbaxy, said, "We are pleased to take this novel formulation of Isotretinoin to the large market in Brazil. I am sure it would prove to be a valuable option for dermatologists and patients who suffer from severe recalcitrant nodular acne. We will utilize our strong front-end capabilities to ensure the availability of this product in Brazil."

Ranbaxy plans to promote the product through a brand dermatology division in Brazil. The isotretinoin formulation is expected to be a flagship product in Ranbaxy's dermatology franchise after it achieves regulatory approval.

Cipher's isotretinoin is a new formulation of isotretinoin, which is used in the treatment of severe recalcitrant nodular acne.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X